SCHEMBL5435525

SCHEMBL5435525

O=c1cc(-c2ccc3[nH]ncc3c2)cc(-c2cccc(Cl)c2)[nH]1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 7/20 0.70
GSK3B P49841 3/20 0.51
CLK2 P49760 2/20 0.51
CDK5 Q00535 2/20 0.51
DYRK1A Q13627 2/20 0.51
CLK4 Q9HAZ1 2/20 0.51
CLK1 P49759 2/20 0.51
DYRK3 O43781 1/20 0.51
CLK3 P49761 1/20 0.51
CDK5R1 Q15078 1/20 0.51
DYRK2 Q92630 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
ROCK2 O75116 3/20 0.51
AURKB Q96GD4 2/20 0.51
ROCK1 Q13464 2/20 0.51
MKNK2 Q9HBH9 2/20 0.51
MAPK13 O15264 1/20 0.51
DAPK3 O43293 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5432014 0.86 CDC7 (0.67) CDC7GSK3BCLK2CDK5DYRK1A
SCHEMBL27074803 0.84 GSK3B (0.70) CDC7GSK3BCLK2CDK5DYRK1A
SCHEMBL4241465 0.82 CDC7 (1.00) CDC7GSK3BCLK2CDK5DYRK1A
SCHEMBL17106449 0.77 CDC7 (0.61) CDC7GSK3BCLK2CDK5DYRK1A
SCHEMBL5416571 0.76 CDC7 (0.70) CDC7GSK3BCLK2CDK5DYRK1A
SCHEMBL8986949 0.76 NOTUM (0.50) PGRBRD4
SCHEMBL10538440 0.74 NOTUM (0.49) CDC7JAK2PGRBRD4
SCHEMBL14350910 0.74 GSK3B (0.54) CDC7GSK3BCLK2CDK5DYRK1A
SCHEMBL18041627 0.71 TGFBR1 (0.83) CDC7GSK3BCLK2CDK5DYRK1A
SCHEMBL5426876 0.71 CDC7 (0.63) CDC7GSK3BCLK2CDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 CDC7, CDC37, CDC73 CDC7 1/4885GSK3B 1106/4885CLK2 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.